Article
Gene Therapy for Paediatric Homozygous Familial Hypercholesterolaemia.
Heart, lung & circulation - 1 Jul 2023
Graves Lara E, Horton Ari, Alexander Ian E, Srinivasan Shubha
Abstract excerpt
The clinical outcome for children and adolescents with homozygous familial hypercholesterolaemia (HoFH) can be devastating, and treatment options are limited in the presence of a null variant. In HoFH, atherosclerotic risk accumulates from birth. Gene therapy is an appealing treatment option as restoration of low-density lipoprotein receptor (LDLR) gene function could provide a cure for HoFH. A clinical trial...
Topics
- Adult
- Adolescent
- Humans
- Child
- Homozygous Familial Hypercholesterolemia
- Hyperlipoproteinemia Type II
- Genetic Therapy
- Phenotype
- Mutation
- Atherosclerosis
